engleski

Thromboprophylaxis for COVID-19-related coagulopathy: what next?

Patients hospitalized with COVID-19 are at high risk for microand macrovascular thromboembolic events due to thromboinflammation and the coagulopathy caused by SARS-CoV-2. Current evidence suggests that anticoagulants other than heparin or antiplatelet therapy do not provide a beneficial effect, but combinations of anticoagulation regimens may be clinically tested. A better distinction between moderate and severe disease should be made, particularly with regard to lung injury and oxygen requirement.

COVID-19 ; Thromboprophylaxis

nije evidentirano